Which company is safer for investors?

Recursion is more diversified and thus less risky, but Summit could yield higher returns if its drug succeeds.

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock to Buy in 2026?

Q: Are either of the companies profitable?

No specific figures were provided, but Recursion generates revenue from partnerships, while Summit is pre-revenue.

This analysis compares Recursion Pharmaceuticals and Summit Therapeutics, highlighting their different approaches to drug development and the associated risks for investors.

June 30, 2026

1 min read

Source: Motley Fool

This article compares Recursion Pharmaceuticals and Summit Therapeutics, two healthcare stocks with contrasting strategies: Recursion uses AI for broad drug discovery, while Summit bets on a single oncology candidate.

Business Model

Recursion Pharmaceuticals

Recursion leverages AI to analyze massive biological data and accelerate drug discovery. It has a diversified pipeline of drug candidates.

Summit Therapeutics

Summit focuses on a single drug candidate (ivonescimab) for cancer treatment, making it a high-risk, high-reward play.

Financial Performance

No specific financial figures were provided, but Recursion generates revenue from partnerships, while Summit is pre-revenue.

Risks

Recursion: AI platform execution risk and competition.
Summit: Concentration risk and clinical trial failure.

Conclusion

The choice depends on risk tolerance. Recursion offers diversification, while Summit offers higher upside with greater risk.

Frequently Asked Questions

Recursion uses AI for broad drug discovery, while Summit focuses on a single oncology drug.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.